ACCESS-IS
Access-IS, part of HID, the leading supplier of software agnostic ticket validators is excited to announce the integration of its VAL100 devices by Masabi. The integration is part of Masabi’s My Fare solution, a contactless mobile ticketing app for Calgary Transit that lets passengers buy tickets and passes anytime, anywhere, using their smartphones. It’s fast, easy, contactless and a safe way to pay and ride transit.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201027005015/en/
The My Fare app, which is powered by Masabi’s Justride platform and can be downloaded from the App Store and Google Play, allows riders of Calgary Transit services to purchase and use fare products such as regular monthly and day passes, airport boarding pass, and single ride tickets directly from their mobile device.
As part of the project over 1000 Access-IS VAL100 ticket validators have been installed across the bus network covering 155 routes. Passengers scan their dynamic and encrypted mobile passes on the devices when boarding the bus, with an audible beep and a colored screen identifying the ticket as valid for use. These validation units will help speed up boarding times making riding Calgary Transit services faster and safer by enabling contactless fare payment and validation. The validation units are powered by Masabi’s Justride Inspect software but also read NFC and contactless EMV (cEMV) technology, giving the agency the flexibility to turn on Account-Based Ticketing and other account-based tokens, if required.
“Calgarians, like citizens in towns and cities around the world, are using smartphones in almost all aspects of their day and made offering the option for riders to use their phone instead of a paper ticket a logical step for Calgary Transit,” said Brian Zanghi, CEO of Masabi. “The change in people’s behaviour brought about by the current requirement for social distancing has made mobile ticketing and the move towards a more contactless journey experience a must-have for transit agencies.”
The VAL100 combines barcode and NFC/RFID reading functionality to provide a single point of presentation for tickets and travel passes – whether presented on a paper ticket, smartcard or mobile phone. It is also available with EMV Level 2 certification, allowing for applications where contactless payments are required. It offers PCI and SRED compliance for contactless payments using VISA, MasterCard, AMEX and Discover payment schemes. It features clear visual and audio passenger feedback, a robust design and a wide range of connection options for installation flexibility.
Speaking about the installation, Bryan Cunningham Regional Sales Manager (Americas) at Access-IS said “It’s always a pleasure to work with Masabi to deliver a ticketing and fare payment solution focused on providing the very best passenger experience whilst protecting the transits agency’s ability to manage fare revenue.”
View source version on businesswire.com: https://www.businesswire.com/news/home/20201027005015/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Brenus Pharma Reports Favorable Tolerability and Clinical Signals in Early Preliminary Results of First-In-Human Study for STC-1010 in Unresectable Metastatic Stage Colorectal Cancer (MSS CRC) Patients6.1.2026 21:00:00 CET | Press release
Brenus Pharma, a clinical stage biotechnology company unlocking the immune system in vivo to fight solid tumors, announced the successful completion of the first dose levels in its ongoing first-in-human study. The multi-center, open-label trial (NCT06934538) is a phase Ia/Ib study designed to evaluate safety, tolerability and preliminary clinical activity of STC-10101 in a first line setting. It will include in vivo analysis of immune and tumor dynamics during dose escalation of treatment and cohort extension to patients with unresectable locally advanced (stage IIIC, T4b) or unresectable metastatic (stage IV) MSS2 colorectal cancer (CRC). Early findings indicate that the first dose levels have been successfully completed with good overall tolerance and no-dose-limiting toxicities observed to date. “We are pleased to report that the safety profile observed to date is good and consistent with our expectations with no DLT,” said Paul Bravetti, CEO of Brenus Pharma. “Moreover, preliminar
SPIE, the International Society for Optics and Photonics, Announces Its 2026 Fellows6.1.2026 20:35:00 CET | Press release
The Society is welcoming 40 new Fellow Members from across the globe SPIE, the international society for optics and photonics, welcomes 40 Members as new Fellows of the Society in the 2026 cohort. They join their Fellow Member colleagues in being honored for their excellent technical achievements, as well as for their substantial service to the optics and photonics community and to SPIE. Fellows are Members of the Society who have made significant scientific and technical contributions in the multidisciplinary fields of optics, photonics, and imaging. Since the Society's inception in 1955, more than 1,800 SPIE Members have become Fellows. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260106630672/en/ SPIE, the international society for optics and photonics, announces its 2026 Fellows This year’s inductees are high-profile leaders in academia, industry, and government, many of whom are particularly prominent in their support
Chemelex Adds Electric Heat Trace Group Ltd.’s SmartTrace Monitoring Platform to its Heat Tracing Portfolio6.1.2026 20:00:00 CET | Press release
Chemelex, a global leader in electric thermal and sensing solutions, today announced the successful completion of its acquisition of substantially all the assets and ongoing operations of Electric Heat Trace Group Ltd. (EHT Group), headquartered in Ontario, Canada. This strategic move marks an exciting start to the new year and reinforces Chemelex’s commitment to delivering smarter, data-driven solutions for industrial heat trace systems. EHT Group is a recognized innovator in heat trace management, offering advanced software, integrated controller solutions, wireless communication modules, and comprehensive field services. Its flagship platform, SmartTrace, is a robust solution available in both cloud-based and on-premises deployments that enables predictive maintenance, minimizes downtime, and provides secure remote monitoring—helping customers achieve greater reliability and operational efficiency. This endeavor will help Chemelex support greater operational efficiencies for our cus
ZIIHERA Plus TEVIMBRA and Chemotherapy: A Potential New Standard for First-Line HER2+ Advanced GEA6.1.2026 19:30:00 CET | Press release
Combination therapy showed compelling survival and disease control compared to current standard, regardless of PD-L1 statusHigh GEA burden in Asia, where BeOne holds ZIIHERA rights, signals potential broad patient impactResults to be presented as a Late-Breaking Abstract Oral Presentation at ASCO GI on January 8, 2026 BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced full results from the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), a HER2-targeted bispecific antibody, in combination with chemotherapy, with and without PD-1 inhibitor TEVIMBRA® (tislelizumab), as a first-line treatment for HER2-positive (HER2+) locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). These data, including the first interim overall survival (OS) analysis, will be presented as a Late-Breaking Abstract Oral Presentation (#LBA285) at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) on
Siemens and NVIDIA Expand Partnership to Build the Industrial AI Operating System6.1.2026 18:07:00 CET | Press release
Through AI, Siemens and NVIDIA are reinventing the entire end-to-end industrial value chain – from design and engineering to manufacturing, production, operations, and into supply chainsSiemens and NVIDIA to build AI-accelerated portfolio including AI-native electronic design, AI native simulation as well as AI driven adaptive manufacturing and supply chainSiemens and NVIDIA to design the next generation of AI factoriesSiemens and NVIDIA to optimize operations through shared innovation CES 2026 - Siemens and NVIDIA today announced a significant expansion of their strategic partnership to bring artificial intelligence into the real world. Together, the companies aim to develop industrial and physical AI solutions that will bring AI-driven innovation to every industry and industrial workflow, as well as accelerate each others’ operations. To support development, NVIDIA will provide AI infrastructure, simulation libraries, models, frameworks and blueprints, while Siemens will commit hundr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
